LETTER FROM THE PRESIDENT

Do you have arthritis? Do any of your friends or family have arthritis? If you answered yes, I’m not surprised since an estimated 50 million Americans suffer from some form of arthritis.

The Arthritis National Research Foundation (ANRF) funds research that will be the key to curing arthritis. And, 91 cents of every dollar donated goes directly into research programs.

We utilize a very rigorous selection process that determines who receives one of our grants. At the Arthritis National Research Foundation, we screen for the innovative theories of young PhD and MD scientists. Cutting-edge research conducted by brilliant young scientists with an idea “outside the box” – this is the niche we fund at the Arthritis National Research Foundation.

This year, our world-renowned Scientific Advisory Board recommended ANRF provide grants for 13 researchers conducting studies in osteoarthritis, rheumatoid arthritis, lupus and related autoimmune diseases at non-profit universities and research institutions nationwide. They are studying the mechanisms of these diseases, as well as ways to translate the science into new treatments.

One of these 13 researchers has the honor of being named “The Sontag Foundation Fellow.” Every year for the past 11 years, a very special family foundation has completely underwritten an ANRF grant. To be named a “Sontag Foundation Fellow” is to be honored as the year’s most promising investigator with a project in rheumatoid arthritis (RA).

In September 2011, Rick and Susan Sontag took their commitment to the highest level, donating $1 million to the ANRF endowment! Thanks to their generous gift, there will be a Sontag Foundation Fellow in perpetuity or until RA is cured. There is no way to adequately express the depth of our gratitude to the Sontag Family. Please take a few moments to view two videos on our website that tell their family’s story, their gift and their commitment to RA research.

Individual donors remain our most ardent supporters. The continued support of over 500 committed individuals each year who give through the Combined Federal Campaign, state campaigns or corporate giving programs is integral to moving this science closer to new treatments and a cure. Each gift brings us one step closer to curing these diseases.

I think you will find we are a committed, effective organization. I invite you to learn more about ANRF at: www.curearthritis.org.

Kevin Donohue, CFP®
President
TRANSPARENCY & ACCOUNTABILITY

ANRF is an Open Book

 Transparency and accountability are extremely important to the Arthritis National Research Foundation. When you give ANRF a gift, over 90% goes directly to arthritis research programs.

Our mission is to fund scientists to cure arthritis by discovering the causes of arthritis and its related diseases including osteoarthritis, rheumatoid arthritis, lupus, juvenile arthritis and other autoimmune diseases.

To accomplish this mission, your donations must go to arthritis research. We want you to hold ANRF accountable to utilize your donations wisely and to be transparent in the process. We are committed to using the donations you have entrusted to us efficiently and effectively in the effort to find a cure.

“Exceeds industry standards and outperforms most charities in its Cause.”

Charity Navigator, the leading independent online charity evaluator, has awarded ANRF its highest rating of four stars four years in a row! Charity Navigator considers this an “exceptional” rating and defines charities with four stars as “exceeding industry standards and outperforming most charities in its Cause.” Please visit the Transparency and Accountability section on CureArthritis.org to learn more or to visit our Charity Navigator profile.

91 cents of every dollar is placed directly into research programs. Research is the key to finding a cure for these diseases. Your donations make it possible.
FINANCIAL REPORT 2011

AUDITED STATEMENT OF PUBLIC SUPPORT, FISCAL YEAR ENDING MARCH 31, 2011

REVENUES AND EXPENSES

PUBLIC SUPPORT AND REVENUE

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and bequests</td>
<td>2,173,600</td>
<td>3,055,844</td>
</tr>
<tr>
<td>Investment Income</td>
<td>713,081</td>
<td>717,266</td>
</tr>
<tr>
<td>Unrealized Gain (loss) on Investments</td>
<td>536,457</td>
<td>565,959</td>
</tr>
</tbody>
</table>

TOTAL SUPPORT AND REVENUE $2,886,681 $3,773,110

EXPENSES

Program Services
Research
Education

Total Program Services $1,201,899 $1,157,465

SUPPORTING SERVICES

Management and General
Fund Development

Total Supporting Services $124,243 $91,842

TOTAL EXPENSES

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Unrestricted Net Assets</td>
<td>1,560,539</td>
<td>2,523,803</td>
</tr>
<tr>
<td>Net Assets at Beginning of Year</td>
<td>5,659,350</td>
<td>3,135,547</td>
</tr>
<tr>
<td>Net Assets at End of Year</td>
<td>7,209,603</td>
<td>5,659,350</td>
</tr>
</tbody>
</table>

STATEMENT OF FINANCIAL POSTION 2011

ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>440,258</td>
<td>603,383</td>
</tr>
<tr>
<td>Accrued Interest</td>
<td>8,014</td>
<td>8,014</td>
</tr>
<tr>
<td>Investments</td>
<td>6,720,648</td>
<td>4,995,384</td>
</tr>
<tr>
<td>Note Receivable</td>
<td>56,415</td>
<td>56,415</td>
</tr>
<tr>
<td>Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Assets</td>
<td>7,225,335</td>
<td>5,664,196</td>
</tr>
</tbody>
</table>

LIABILITIES AND NET ASSETS

LIABILITIES

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable</td>
<td>5,446</td>
<td>4,846</td>
</tr>
</tbody>
</table>

NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>7,209,603</td>
<td>5,649,084</td>
</tr>
</tbody>
</table>

TOTAL LIABILITIES AND NET ASSETS $7,225,335 $5,664,196
The kindness and generosity of the American spirit is alive and well in the Sontag family. Originally from Southern California, Rick and Susan Sontag are working quietly to improve the lives of millions around the country.

Together they preside over The Sontag Foundation, a private family foundation based in Ponte Vedra Beach, Florida.

For the past eleven years, The Sontag Foundation has partnered with the Arthritis National Research Foundation to completely fund a rheumatoid arthritis research grant. A luncheon to honor Rick and Susan’s commitment to arthritis research was held September 30, 2011 at the Long Beach Yacht Club.

Moved by the luncheon in their honor, Rick and Susan had a surprise of their own.

“You have come to us every year, requesting our support,” began Rick Sontag. “Instead of coming to us each year, Susan and I would like to bring you a check when we come out for the luncheon – for $1 million!”

“A gift of this size ensures there will be a Sontag Foundation Fellow for Rheumatoid Arthritis Research in perpetuity,” said Arthritis National Research Foundation Board of Director’s President, Kevin Donohue. “This funding will enable us to support more arthritis research towards a cure.”

“My mother suffered the devastating effects of rheumatoid arthritis for over 35 years and it finally ended her life,” said Rick, explaining his family’s heartbreaking connection to this autoimmune disease.

Rick and Susan Sontag still have a special affinity for Long Beach and Southern California as both grew up there and are graduates of Woodrow Wilson High School, class of 1960. Close with their family, Rick and Susan return frequently to visit the many family members and friends who still reside in Long Beach.

The Sontag’s built a business, raised three children and currently reside in Ponte Vedra Beach. After the sale of their business in 2002, Rick and Susan turned full-time to philanthropy – funding cutting-edge brain cancer and rheumatoid arthritis research and improving lives for those less fortunate than they in their northeast Florida community.

“ANRF’s Scientific Advisory Board conducts the in-depth reviews of the applicants,” said Rick Sontag. “Once they’ve decided who deserves the research funding, we do our own internal review and choose which ANRF rheumatoid arthritis project and scientist we will support.”

Two Sontag Foundation Fellows of the Arthritis National Research Foundation were in attendance at the September 30th luncheon. Ioannis Adamopoulos, PhD, of the University of California, Davis, and Joyce Wu, PhD, of the University of Arizona both gave descriptions of the research funded by the Arthritis National Research Foundation and The Sontag Foundation.

Rick and Susan Sontag have come full circle back to their Long Beach roots by supporting a locally-based nonprofit with a national scope working to make a difference in the lives of 50 million Americans afflicted with arthritis. The Sontag’s gift will positively impact science into the future, potentially funding the next breakthrough for new treatments and a cure.

“The Arthritis National Research Foundation is an efficient steward of charitable dollars invested in arthritis research grants,” continued Sontag. “That’s why we are proud to partner with ANRF to fund cutting-edge research.”

View Rick’s story and the presentation of their gift at CureArthritis.org. To join the Sontag’s in supporting this exciting research you may make a donation today.
IMPORTANCE OF COLLABORATION

The Sontag Foundation: Partners in Research

The Sontag Foundation is a family foundation located in Ponte Vedra Beach, Florida. The emphasis of their giving is to support young investigators studying the causes of and new treatments for brain cancer.

They are also passionate about finding a cure for rheumatoid arthritis and, after careful consideration of nonprofit organizations across the U.S., they chose to partner with the Arthritis National Research Foundation 11 years ago. In each of those 11 years, the Sontag Foundation completely funded an ANRF researcher.

In 2011, they decided to take their giving to the highest level, making a $1 million gift to the ANRF endowment, ensuring that there will be a Sontag Foundation Fellow in perpetuity or until RA is cured.

Our collaboration is to fund the best and brightest young minds seeking a cure for RA.

Read more about this amazingly generous family on page 10 of this report and please visit the curearthritis.org website to view a video of Rick Sontag sharing the heartwarming story behind their generosity and commitment to RA research.

Joining Forces to Fund Psoriatic Arthritis Study

ANRF is delighted to collaborate with the National Psoriasis Foundation (NPF) to fund a two-year, $200,000 translational research grant focused on psoriatic arthritis. Elaine Husni, PhD, MPH, of the Cleveland Clinic in Ohio is examining evidence that psoriatic arthritis patients are at increased risk for heart disease by studying the connections between joint inflammation and cardiovascular inflammation.

Dr. Husni’s study will help identify and characterize the cardiovascular biomarkers in psoriasis and psoriatic arthritis that may allow earlier detection of those patients at risk for heart disease.

ANRF and the NPF are both committed to research. A collaborative effort such as this grant enables a cohesive team of scientists in rheumatology, dermatology and cardiology to come together to conduct innovative research that would not traditionally be possible.
Nearly $1 million in arthritis research grants was awarded to 13 scientists this year. These young, post-doctoral investigators with cutting-edge research ideas represent the top 16% of all applicants.

ANRF’s highly competitive, NIH-level review process conducted by its world-renowned Scientific Advisory Board ensures that only the top tier applicants and projects are funded.

<table>
<thead>
<tr>
<th>Area of Study</th>
<th>Scientist</th>
<th>Research Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid Arthritis</td>
<td>Ioannis Adamopoulos, D.Phil</td>
<td>University of California</td>
</tr>
<tr>
<td></td>
<td>Massimo Bottini, Ph.D.</td>
<td>Davis, CA</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Greenberg, M.D., MPH</td>
<td>Sanford-Burnham Medical Research Institute</td>
</tr>
<tr>
<td></td>
<td>Hye-Jung Kim, Ph.D.</td>
<td>La Jolla, CA</td>
</tr>
<tr>
<td></td>
<td>Peter Nigrovic, M.D.</td>
<td>New York University School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>New York, NY</td>
</tr>
<tr>
<td>Juvenile Arthritis</td>
<td>Altan Ercan, Ph.D.</td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>Yingcui Li, Ph.D.</td>
<td>Brigham &amp; Women’s Hospital</td>
</tr>
<tr>
<td></td>
<td>Xin Li, M.D., Ph.D.</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Lupus</td>
<td>Jian Zhao, Ph.D.</td>
<td>University of Connecticut Health Center</td>
</tr>
<tr>
<td></td>
<td>Julie Zikherman, M.D.</td>
<td>Farmington, CT</td>
</tr>
<tr>
<td>Lupus &amp; RA</td>
<td>Brian Skaggs, Ph.D.</td>
<td>Rush University Medical Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>Anklosing Spondylitis</td>
<td>Judith Smith, M.D., Ph.D.</td>
<td>University of California</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>Psoriatic Arthritis</td>
<td>Elaine Husni, M.D., M.P.H.</td>
<td>University of California</td>
</tr>
<tr>
<td></td>
<td></td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of California</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Wisconsin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Madison, WI</td>
</tr>
</tbody>
</table>

Three New Lupus Genes Discovered: ANRF Grantee Part of Worldwide Study

Courtney Montgomery, PhD, of the Oklahoma Medical Research Foundation and 2009-2010 ANRF grant recipient, is part of a team of scientists from around the world conducting large-scale genetic testing in lupus.

They recently published the discovery of three new lupus genes that show statistical significance for lupus risk in the American Journal of Human Genetics. Dr. Montgomery’s role in this study is part of her ANRF grant project.

“Identifying these three genes in a variety of ethnic groups tells us quite a bit about lupus,” says Dr. Montgomery. “First, we learned that the genes that cause lupus vary across populations; 2) there is a complex system of genes at play in lupus, and 3) the identification of these genes will help us understand and treat this devastating disease.”

Continue to the next page to learn more about the research we are funding or visit us at curearthritis.org
OSTEOARTHRITIS RESEARCH

Osteoarthritis, the most prevalent form of arthritis, is due to “wear and tear” of joint tissues, causing inflammation and damage. More than 20 million Americans suffer with osteoarthritis (OA), according to the Centers for Disease Control.

The Arthritis National Research Foundation is committed to funding cutting-edge research to find new and more effective ways to treat OA. Here are a few of the current research projects underway by ANRF grant recipients:

**Shigeru Miyaki, Ph.D.** at The Scripps Research Institute discovered a natural molecule in the body that regulates the growth of cartilage. These findings could lead to new methods to repair and replace damaged cartilage in individuals with OA.

**Mai Thuy Lam, Ph.D.** at Stanford University is conducting studies to replace damaged meniscus tissues in knee joints with adult stem cell transplants. Replacement of damaged and worn out tissues with a transplant of the patient’s own stem cells may regenerate normal healthy tissue and restore joint function.

**Timothy Griffin, Ph.D.** at Oklahoma Medical Research Foundation is studying how cartilage breaks down in the process of developing OA. He hopes to identify new therapeutic approaches to treat osteoarthritis, particularly in the context of joint injury, obesity, and aging.

ANRF is hopeful that these studies and others will provide insight for new and more effective therapies to be developed in the near future. To see more of the latest research visit [CureArthritis.org](http://CureArthritis.org)
First new drug in 50 years approved

Last March, the FDA approved belimumab, known as Belvyta, for the treatment of adults with systemic lupus erythematosus (SLE), or lupus. It is the first drug specifically approved for treating lupus in over 50 years.

Patients receive intravenous infusions at two-week intervals for six weeks, then four-week intervals thereafter. Belimumab is in a class of medications called monoclonal antibodies. It works by blocking the activity of a certain protein in people with lupus. This helps control lupus, but does not cure it.

ANRF funds studies in lupus research every year because discoveries about the human immune system have implications for all autoimmune diseases— including lupus, rheumatoid arthritis and other non-articular autoimmune diseases such as Type I Diabetes and MS.

What’s next in Lupus Research?

Betty Tsao, PhD, Professor of Medicine at UCLA and former ANRF grant recipient, was the first person to link a specific human chromosome region to increased risk of developing lupus.

According to Dr. Tsao, genetic susceptibility is the single greatest risk factor for lupus. Currently, her laboratory has gathered specimens from approximately 300 families that contain two or more members with lupus, as well as from thousands of lupus patients with differing ancestral backgrounds.

Using these resources, Dr. Tsao has identified multiple genetic risk factors for lupus, and they are working towards understanding the underlying molecular and cellular mechanisms contributing to lupus.

The Arthritis National Research Foundation funded Dr. Tsao’s early work in 1993; since then, we have funded two other young researchers in her lab to help move this science forward.

“We hope results of these studies will enhance our understanding of lupus initiation and progression, identifying novel targets for therapies, and improving the diagnosis and prognosis of patients in the future,” says Dr. Tsao.
Gale “Morrie” Granger, Ph.D.
University of California, Irvine
Professor of Immunology, Retired

Dr. Granger was a Professor of immunology at the University of California, Irvine, for 40 years and a consultant to numerous hospitals, research institutes and the National Institutes of Health (NIH). He has served on the Arthritis National Research Foundation Board of Directors since 1990, including as president from 1997-99. It was his vision and guidance that led to the establishment of ANRF’s Scientific Advisory Board in 1998.
It’s been 40 years since Dr. Gale “Morrie” Granger first learned about the Arthritis National Research Foundation (ANRF). At the time, ANRF was a small foundation in Long Beach making research grants in California only.

“I was a young faculty member at UCI,” says Granger, “and my research findings did not agree with the current thinking of how the immune system caused cell and tissue damage. After the ANRF directors visited my lab and reviewed the results, they decided to support our then-controversial studies.”

Dr. Granger developed a new way of looking at how white blood cells cause tissue damage. Granger’s team discovered that white blood cells could release tissue destructive molecules, initially called lymphotoxins (LT) and later termed tumor necrosis factors (TNF). After initial support from ANRF, Dr. Granger continued to study and characterize LT and TNF. These studies led to the discovery that cells can produce materials that inhibit LT/TNF activity.

Then, in collaboration with the biotech company, Genentech, they characterized the inhibitor. It turned out to be a soluble form of the LT/TNF cell receptor. These studies led the way for the use of drugs that block LT/TNF to be developed into treatments for rheumatoid arthritis and other autoimmune diseases.

Collectively, these drugs are termed “biologics.” Today’s most effective biologic treatments for RA and other autoimmune disorders are anti-TNF drugs, such as Enbrel, Humira and Remicade. Without Dr. Granger’s discovery, none of these therapies would exist.

Dr. Granger was a Professor of Immunology at UCI where he taught and conducted research for 40 years.

“When the Arthritis National Research Foundation called me about 20 years ago asking if I would serve on the Board of Directors and help with the grant review process, how could I say no?” said Dr. Granger.

Since then, he has been a driving force for ANRF, developing the Scientific Advisory Board and guiding the Foundation’s growth and programs so that today it is a respected national organization.

He made discoveries in the lab that resulted in new therapies for RA and changed the understanding of the immune system. Now forty years later, he gives back every day by helping ANRF fund cutting-edge arthritis research projects conducted by top young investigators.

“These young scientists are where I was 40 years ago,” said Dr. Granger. “And, they are the ones with the best chance of making the next breakthrough discovery for the millions of Americans with OA, RA and autoimmune diseases.”

To learn more about Dr. Granger and his involvement with the Arthritis National Research Foundation visit us at curearthritis.org
CureArthritisBlog.com

At the Arthritis National Research Foundation we are committed to funding research to find a cure for arthritis. We believe that research is the key to finding new and better treatments and a cure. However, we know that people are suffering the effects of arthritis today and their stories are integral to the fight against arthritis.

You are the reason we work so hard to find a cure and your story deserves to be told. The rest of America must understand that arthritis is our country’s number one disability, affecting an estimated 50 million adults and children. It literally touches every American family and it is time we stand together and find a cure.

CureArthritisBlog.com is designed to be a tool to share your story. We feature stories from around the country, creating a community of support and shared interest. Your stories inspire all of us at the Arthritis National Research Foundation to work that much harder and they inspire thousands of others to get involved to make a difference.

From your personal stories to arthritis research news to Racing For A Cure, CureArthritisBlog.com is showcasing the amazing men, women and children fighting these debilitating diseases. See their stories, share your story, and join us in the fight against arthritis.

The faces of arthritis

Go BLUE for Arthritis!

MAY IS ARTHRITIS AWARENESS MONTH

Contact the ANRF office to get your awareness gear!
Racing For A Cure raises awareness about arthritis and the critical need for arthritis research through sport. Whether you are a runner, walker, biker, swimmer or tri-athlete, we want you to join the team!

The program is simple and the personal satisfaction is unparalleled. It always feels great to complete that 5K, half marathon or tri-event, but completing your race and knowing you have raised awareness along the way, makes it that much better.

With an estimated 50 million Americans afflicted, demonstrating your support to help end America’s #1 disability means everything. And, you will race with more heart thinking of those who suffer with arthritis.

Individuals from Southern California, New York, Virginia, Florida and Mississippi are Racing For A Cure, and we want you too!

We want more team members, more awareness, and a larger family in the fight against arthritis.

It’s easy: contact Marketing Director, Derek Bellisle, at derek@curearthritis.org and tell him you want to join the team! Provide your name, email, jersey size and mailing address. He will create a fundraising page and mail you a package to get started.

Please note that it is not a requirement of the program to raise money, it is only a requirement to help us raise awareness. However, if you raise $1,000, we will refund the entry fee for your race as a thank you! Looking forward to hearing from you – or friends and family who like to race – and sending you a Racing For A Cure racing kit!

---

**Kids Get Arthritis Too**

**Did you know?**
300,000 children
have arthritis

Dalton, Age 12

Bailey, Age 6

Jordan, Age 10

We need your help to find a cure!
Make a donation at [CureArthritis.org](http://CureArthritis.org)
ARThRITIS NATIONAL RESEARCH FOUNDATION
200 Oceangate, Suite 830 • Long Beach, CA 90802-4335 • 800-588-CURE

OFFICERS AND DIRECTORS

Kevin Donohue, President
Morgan Stanley Smith Barney

Shaun Skeels, Vice-President
Anfield Capital Management

Kelly Rouba, 2nd Vice-President
FU Division of Developmental Disabilities

Mark Schulten, Secretary-Treasurer
Wells Fargo Advisors – The Schulten Group

Vic Braden
Vic Braden Tennis Colleges

Kathryn Ferris
Morgan Stanley Smith Barney

Scott Green
Chapard

Gale Gronger, Ph.D.
University of California, Irvine

Marli Krupin
Gilbert Krupin Life Insurance

Krish McPherson
LPGA Golf Professional

Britt Meyer
Meyer Properties

Lynn Moyer
Attorney at Law

James Rose, Pharm.D.
CareMore Health Plan

The Hon. Sally Anne Sheridan
From Real Estate Group

Kathleen Tepkey
Los Angeles Consulting Group

Carl Ware, Ph.D.
Sanford-Burnham Medical Research Institute

SCIENTIFIC ADVISORY BOARD

Carl Ware, Ph.D., Chairman
Sanford-Burnham Medical Research Institute

Josi Buxbaum, M.D.
The Scripps Research Institute

Mary K. Crow, M.D.
Hospital for Special Surgery

Bevra Hohn, M.D.
UCLA School of Medicine

Hal Hoffman, M.D.
University of California, San Diego

Martin K. Lotz, M.D.
The Scripps Research Institute

Hugh McDevitt, M.D.
Stanford University Medical Center

Grate Sunderschupp-McDevitt, M.D.
Stanford University Medical Center

Robert Terkeltdub, M.D.
University of California, San Diego

Emeritus

Gale Gronger, Ph.D.
University of California, Irvine

Eng Tan, M.D.
The Scripps Research Institute

Special thanks to our CFC donors!
CFC # 11031
Please remember us again this fall!

A portion of this annual report generously underwritten by

PSP
print solutions provider
714.586.8870
info@printsolutionpr.com
www.printsolutionpr.com

“Our mission is a simple one... use our expertise to create marketing tools that work better to attract... to educate... to inspire.”

DESIGN  PRINT  APPAREL

New ideas... better solutions.